Investigating T cell changes in patients experiencing side effects from cancer immunotherapy
Official title: Single-cell dissection of CD4 T cell changes in patients with immune-related adverse events following PD-1 inhibition
Funded at University of Pennsylvania · NIH-11012869 · Data updated 2026-11-12
This study is looking at how a type of cancer treatment called PD-1 therapy can sometimes cause side effects related to the immune system, and it will compare patients who have these side effects with those who don’t to better understand why they happen and how vaccinations might help identify any hidden immune problems.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | February 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $172,724 |
| NIH project number | 5K08AR081929-03 |
| Project ID | NIH-11012869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients receiving PD-1 immunotherapy who may experience immune-related adverse events.
✕Less likely to help
Patients not undergoing PD-1 immunotherapy or those who do not experience immune-related adverse events may not benefit from this research.
What this research studies
This research focuses on understanding how PD-1 checkpoint inhibition, a type of cancer immunotherapy, can lead to immune-related adverse events (irAEs) in patients. The study will analyze two groups of patients: one group receiving PD-1 therapy who develop irAEs and another group who do not. By examining the differences in CD4 T cell behavior and characteristics between these groups, the research aims to uncover the mechanisms that trigger these adverse effects. Additionally, the study will explore how vaccination may reveal underlying immune issues in patients experiencing irAEs.
Why it matters
Potential benefit: If successful, this research could lead to better management and prevention of immune-related side effects in patients undergoing PD-1 immunotherapy.
How similar studies have gone: Previous research has shown promising results in understanding immune responses related to PD-1 inhibition, indicating that this approach may yield valuable insights.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Apostolidis, Sokratis — University of Pennsylvania
- Study coordinator: Apostolidis, Sokratis
Related research
Other NIH-funded projects on the same topics.
-
Comparing universal and guideline-directed genetic testing for young adults with cancer
This study is looking at whether a broader genetic test can help young adults with cancer find inherited risks that regular tests might miss, so they can get better treatment and care tailored just for them.
-
Better, searchable data for human pain biology
A data integration center will standardize, combine, and share molecular and cellular data from human pain research to help scientists understand how pain works and to accelerate discoveries.
-
Understanding how sweat glands form and work to help burn and skin injury patients
A study at the University of Pennsylvania looks at how sweat glands develop and function, with the goal of informing treatments for people who suffer traumatic skin injuries.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Understanding how a special airway cell helps protect and repair breathing passages
A researcher is studying a newly found airway cell called the hillock to see how it protects the airways and helps repair them after injury, with the aim of helping people with asthma, COPD, or bronchiectasis.
-
Defining TMJ cartilage progenitors and their regulatory niche for TMJ regeneration
Researchers are studying the cells that could help repair the jaw’s cartilage in TMJ osteoarthritis to lay the groundwork for regenerative therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.